ReviewHematology. American Society of Hematology. Education Program2020
Neuropathic pain in sickle cell disease: measurement and management.
Review in Hematology. American Society of Hematology. Education Program, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 13 citations in OpenAlex.
- Evaluation of non-opioid therapies for pain management of sickle cell disease: a literature-based review.Annals of hematology · 2026Review
- Preliminary Benefits of In-Home Virtual Reality for Chronic Pain in Sickle Cell Disease: Pilot Randomized Trial.Biomedicines · 2026Article
- Sickle cell vaso-occlusive episodes correlate with the magnetic heterogeneity of red blood cells.Blood advances · 2026Article
- Chronic pain in the aging adult with sickle cell disease.Frontiers in pain research (Lausanne, Switzerland) · 2026Review
- Aging with Thalassemia and Sickle Cell Disease: A Gerontological Model of Accelerated Multimorbidity and Function-Centered Care Beyond Midlife.Mediterranean journal of hematology and infectious diseases · 2026Review
- Behavioral and transcriptional effects of age in HbSS-BERK humanized SCD mice.Journal of sickle cell disease · 2025Article
- Clinical phenotype of high-impact chronic pain in sickle cell disease at consultation for hematopoietic cell transplant.Journal of sickle cell disease · 2025Article
- Article
- Article
- Article
- Prevalence of neuropathic pain in adolescents with sickle cell disease: A single-center experience.Pediatric blood & cancer · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The identification of chronic pain and neuropathic pain as common contributors to the overall pain experience of patients with sickle cell disease (SCD) has altered the way we should evaluate difficult-to-treat pain. The recognition of these 2 entities is not generally routine among various medical specialties and provider levels that treat SCD. Due to the relative recency with which neuropathic pain was first described in SCD, validated assessment tools and evidence-based treatments remain lacking. Although clinical assessment and judgment must continue to inform all decision making in this understudied area of SCD pain management, a number of validated neuropathic pain assessment tools exist that can make possible a standardized evaluation process. Similarly, investigation of available neuropathic pain treatments for the uniquely complex pain phenotypes of SCD has only just begun and is better established in pain conditions other than SCD. The aim of this review is to briefly summarize the proposed basic pathophysiology, assessment, and treatment of neuropathic pain in patients with SCD. Furthermore, the aim of this review is to encourage an expanded framework for the assessment and treatment of SCD pain that appreciates the hidden complexities of this common complication of SCD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.